ClinicalTrials.Veeva

Menu

Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy

IlDong Pharmaceutical logo

IlDong Pharmaceutical

Status

Unknown

Conditions

Hypertension
Dyslipidemias

Study type

Observational

Funder types

Industry

Identifiers

NCT03742544
ID-TERO-401

Details and patient eligibility

About

Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)

Full description

Telostop TAB is fixed-dose combination of telmisartan and rosuvastatin, which was approved in 2015 in the Republic of Korea for the treatment of patients with hypertention and dyslipidemia. A post-marketing surveillance was conducted following the approval to obtain data on the safety and efficacy of Telostop TAB in real-world practice.

Enrollment

600 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The patient who is first prescribed and administered Telostop plus Tab.

Exclusion criteria

  • The patients who are overreacting to this drug or its components
  • The patients to the "Do not administer to the next patient" section of the approved instructions for use

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems